{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '7.8.', 'Treatment after the End of the Study', 'The investigator is responsible for ensuring that consideration has been given to the post-', \"study care of the participant's medical condition.\", 'Refer to Section 9 and the SOA (Table 3) for follow-up assessments of participants who', 'are to be followed for disease progression and survival after they permanently', 'discontinue from study treatment.', '8.', 'DISCONTINUATION CRITERIA', '8.1.', 'Discontinuation of Study Treatment', 'Participants will receive study treatment until disease progression, unacceptable toxicity,', 'or death (including but not restricted to meeting stopping criteria for significant toxicity', 'as outlined in Section 8.1).', 'Study treatment may be permanently discontinued for any of the following reasons:', 'disease progression or unacceptable toxicity.', 'participant has met any of the protocol defined safety stopping criteria', '(Section 7.2).', 'deviation(s) from the protocol', 'request of the participant or proxy (withdrawal of consent by participant or', 'proxy)', \"investigator's discretion\", 'concurrent illness that prevents further administration of study treatment(s)', 'pregnancy', 'participant is lost to follow-up', 'study is closed or terminated', 'The primary reason study treatment was permanently discontinued must be documented', \"in the participant's medical records and electronic case report form (eCRF)\", 'If the participant voluntarily discontinues from treatment due to toxicity, AE (adverse', 'event) must be recorded as the primary reason for permanently discontinuation on the', 'eCRF.', 'Once a participant has permanently discontinued from study treatment, the participant', 'will not be allowed to re-enter the study.', 'All participants who discontinue from study treatment for any reason other than', 'confirmed progression or death will complete safety assessments, and will be followed up', 'for PFS, OS, and subsequent anti-cancer therapy after study as specified in the SOA', '(Table 1).', '66']['2017N330177_04', 'CONFIDENTIAL', '205678', 'PFS Follow-up:', 'All participants who permanently discontinue study treatment in the absence of disease', 'progression will remain in the study and will be followed for progression according to the', 'protocol schedule until:', 'New anti-cancer therapy is initiated', 'Progression is documented, or', 'Death occurs', 'OS Follow-up:', 'All participants who permanently discontinue study treatment will be followed for', 'survival and new anti-cancer therapy until the end of study as described in Section 5.3.', 'Withdrawal from Study Treatment:', 'A participant may withdraw from study treatment at any time at his/her own request, or', 'may be withdrawn at any time at the discretion of the investigator for safety, behavioral', 'or administrative reasons. If a participant withdraws from the study, he/she may request', 'destruction of any samples taken, and the investigator must document this in the site', 'study records.', '8.2.', 'Safety Stopping Criteria', '8.2.1.', 'Liver Chemistry Stopping Criteria', 'Liver chemistry stopping and increased monitoring criteria have been designed to', 'assure participant safety and evaluate liver event. The diagram below illustrates Liver', 'Stopping Event Algorithm (Figure : 3)', '67']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Figure 3', 'Liver Chemistry Stopping Criteria - Liver Stopping Event Algorithm', 'If subject to be monitored weeklymustreferto Liver Safety Required Actions and Follow up', 'Assessments section in the Appendix', 'Continue Study Treatment', 'Plus', 'No', 'Bilirubin22x', 'Yes', 'No', 'ULN (>35%', 'ALT23xULN', 'ALT>3xULN', 'ALT>3xULN', 'direct)', 'Plus', 'Yes', 'No', 'No', 'No', 'but able to', 'Yes', 'persist for', 'ALT23xULN', 'orplus', 'Symptoms of', 'ALT>5xULN', 'monitor', '4 weeks or', 'INR>1.5, if', 'liverinjury', 'weekly for', 'stopping', 'measured\"', 'or', '4 weeks', 'criteria', 'Possible', 'hypersensitivity', 'met', \"Hy's Law\", 'Yes', 'Yes', 'No', 'Yes', 'Yes', 'Discontinue Study Treatment', 'Mustrefer to Liver Safety Required Actions and Follow up Assessments section in the Appendix', \"Reportas an SAE if possible Hy's Law case: AL Tz3xULN and Bilirubin22xULN (>35% direct) or\", 'INR>1.5 if measured*', '\"INR valu e not applicable to subjects on anticoagulants', 'The details on follow up procedures are outlined in Appendix 7.', '8.2.2.', 'Study Treatment Restart or Rechallenge', 'If participant meets liver chemistry stopping criteria do not restart/rechallenge participant', 'with study treatment unless:', 'GSK Medical Governance approval is granted (as described below),', 'Ethics and/or IRB approval is obtained, if required, and', 'Separate consent for treatment restart/rechallenge is signed by the participant', 'If GSK Medical Governance approval to restart/rechallenge participant with study', 'treatment is not granted, then participant must permanently discontinue study treatment', 'and may continue in the study for protocol-specified follow up assessments.', '8.2.3.', 'QTc Interval Stopping Criteria', 'If a participant that meets the corrected QT (QTc) interval duration criteria below, study', 'treatment(s) will be withheld.', \"QT interval corrected for heart rate by Fridericia's formula (QTcF = QT\", '/', 'RR 0.33) > >530 msec', 'OR', '68']\n\n###\n\n", "completion": "END"}